Literature DB >> 3757154

The antiproliferative properties of tamoxifen and phenothiazines may be mediated by a unique histamine receptor (?H3) distinct from the calmodulin-binding site.

L J Brandes, R P Bogdanovic, M D Cawker, R Bose.   

Abstract

N,N-diethyl-2-[(4-phenylmethyl)-phenoxy]-ethanamine HCl (DPPE), a novel histamine antagonist (?H3), which selectively binds with high affinity to the antiestrogen-binding site (AEBS/?H3), inhibits the activity of calmodulin-dependent myosin light chain kinase (MLCK) only at concentrations greater than 1 mM, as opposed to tamoxifen (TAM), which has an IC50 = 4 microM in the same assay. This suggests that the antiestrogen-binding site is distinct from the site on calmodulin which binds TAM and phenothiazines. However, at an in vitro concentration of 1 X 10(-6) M, the antiproliferative effects of DPPE and several phenothiazines, which also compete for binding to AEBS/?H3, are about equal; this suggests that affinity for AEBS/?H3 rather than that for the calmodulin-binding site may correlate with clinically relevant antigrowth effects of these compounds.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757154     DOI: 10.1007/bf00253057

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological role.

Authors:  L J Brandes
Journal:  Biochem Biophys Res Commun       Date:  1984-10-15       Impact factor: 3.575

2.  Antiestrogenic effect of trifluoperazine in mice.

Authors:  S D Lyman; V C Jordan
Journal:  Biochem Pharmacol       Date:  1985-06-15       Impact factor: 5.858

Review 3.  Role of histamine in mediation of hormone action.

Authors:  C M Szego
Journal:  Fed Proc       Date:  1965 Nov-Dec

4.  Evidence that tamoxifen is a histamine antagonist.

Authors:  E A Kroeger; L J Brandes
Journal:  Biochem Biophys Res Commun       Date:  1985-09-16       Impact factor: 3.575

5.  Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists.

Authors:  W N Hait; G L Lee
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

6.  Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.

Authors:  H Y Lam
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

7.  New evidence that the antiestrogen binding site may be a novel growth-promoting histamine receptor (?H3) which mediates the antiestrogenic and antiproliferative effects of tamoxifen.

Authors:  L J Brandes; R P Bogdanovic
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

8.  A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes.

Authors:  L J Brandes; M W Hermonat
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

9.  Identification of high affinity estrogen binding sites in calf uterine microsomal membranes.

Authors:  I Parikh; W L Anderson; P Neame
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

10.  Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin.

Authors:  W N Hait; L Grais; C Benz; E C Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more
  3 in total

1.  Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site.

Authors:  F Mésange; M Sebbar; B Kedjouar; J Capdevielle; J C Guillemot; P Ferrara; F Bayard; F Delarue; J C Faye; M Poirot
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

3.  Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

Authors:  E A Lien; K Wester; P E Lønning; E Solheim; P M Ueland
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.